Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00701337
Other study ID # 0507402
Secondary ID
Status Completed
Phase Phase 4
First received February 22, 2007
Last updated May 10, 2017
Start date September 2006
Est. completion date January 2010

Study information

Verified date May 2017
Source University Hospital, Toulouse
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this pilot study conducted in post-menopausal women is to evaluate the effect of 17ß-estradiol administration on inflammatory-immune cells, namely antigen-presenting cells (monocytes/dendritic cells), and more precisely on their activation by inflammatory stimuli. This study will allow us to determine our ability to recruit menopausal women and to characterize the optimal primary end-point among the numerous criteria tested


Description:

Although the beneficial effects of hormonal replacement therapy (HRT) against osteoporosis and climacteric symptoms have been clearly established, randomized studies recently revealed that the combined administration of oral estrogens and medroxyprogesterone acetate increases the incidence of coronary events and strokes during the first months of treatment. Furthermore, oral estrogens significantly enhance IL-6 and CRP secretion. This increase in the plasma concentration of inflammatory markers probably results from a direct effect of oral administration on the liver, since i twas not observed with estrogens administered by transdermal route.

Our experimental data in ovariectomized mice demonstrated that the chronic subcutaneous administration of17ß-estradiol (E2) enhances the expression of pro-inflammatory cytokines by Th1 lymphocytes, Natural Killer T cells and monocytes/macrophages. This pro-inflammatory effect of E2 could play a role in the deleterious vascular effects observed in randomized studies, especially by favoring plaque instability.

Our aim is to determine whether E2 administration in menopausal women leads to an inflammatory phenotype of circulating antigen-presenting cells, especially monocytes. Indeed, evaluating the inflammatory status at the cellular level probably gives more precise informations than plasma cytokine concentrations to predict the ability of estrogens to enhance inflammatory processes. We first propose a pilot study in order to determine enrollment feasibility, as well as the optimal biological endpoints to assess monocyte activation status. These latter criteria will be then used in a future randomized study comparing two routes of E2 administration (oral vs transdermal).

The present study will include 34 menopausal women. After the inclusion visit, three visits will be performed with the collection of a 50 ml blood sample and the isolation of circulating immune cells (monocytes).

The following criteria will be studied before (V1 and V2) and after 30 ± 3 days of E2 treatment (V3:

1. expression of surface activation molecules.

2. Secretion of cytokines in response to several Toll-like receptor stimuli.

3. IL-6 and CRP-US plasma concentrations.

We will first assess the intra-individual variability (V1 and V2). At visit 2 (V2), the subjects will be randomized to receive E2 either by oral (n= 17) or transdermal (n= 17) route.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date January 2010
Est. primary completion date January 2010
Accepts healthy volunteers No
Gender Female
Age group 45 Years to 60 Years
Eligibility Inclusion Criteria:

- Women with confirmed menopause (duration : 1 to 5 years)

- No contra-indication of hormonal replacement therapy due to medical history

- Mammogram without significant abnormality (< 12 months)

- Normal body mass index (BMI) (19 = IMC = 25 kg/m2)

- No treatment with estrogens and/or progestatives and/or SERM (specific moduator of estrogen receptor) and/or phytoestrogènes ongoing or stopped for less than 3 months

- No clinical or biological abnormality or treatment indicating the presence of an infectious or inflammatory disease.

- No participation to another clinical study during the 3 months before the inclusion

- Ability to sign the consent form.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
oestradiol
oestradiol 2 mg oral route 30 days
oestradiol
oestradio transdermal patch 60ug by 24 hours 30 days

Locations

Country Name City State
France University Hospital Toulouse Toulouse

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Toulouse

Country where clinical trial is conducted

France, 

References & Publications (1)

Seillet C, Laffont S, Trémollières F, Rouquié N, Ribot C, Arnal JF, Douin-Echinard V, Gourdy P, Guéry JC. The TLR-mediated response of plasmacytoid dendritic cells is positively regulated by estradiol in vivo through cell-intrinsic estrogen receptor a sig — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary To determine the feasibility of a future multicentric randomized trial : estimation of the number of subjects required 1 month
Secondary variability and repeatability of the biological parameters studied number of circulating immune cells, expression of surface molecules by monocytes, secretion of cytokines following TLR activation 1 month
Secondary Feasibility of the recruitment, enrollment and follow-up of menopausal women End of study
See also
  Status Clinical Trial Phase
Completed NCT02235051 - Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors N/A
Completed NCT01635413 - Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial) N/A
Recruiting NCT04705623 - Influence of Iyengar Yoga on the Bio-functional Age of Postmenopausal Women N/A
Withdrawn NCT03238703 - Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer Phase 4
Completed NCT03756272 - Stellate Ganglion Block to Reduce Hot Flushes N/A
Recruiting NCT03953157 - Dietary and Exercise Interventions in Reducing Side Effects in Patients With Stage I-IIIa Breast Cancer Receiving Aromatase Inhibitors N/A
Completed NCT00338728 - Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer Phase 2
Completed NCT01482702 - Impact of Weight Loss Interventions for Overweight Breast Cancer Survivors N/A
Not yet recruiting NCT05009238 - Effect of l S Exercises on Balance and Spatiotemporal Gait Parameters in P M Women N/A
Terminated NCT01842217 - Validation of [18F]FES for Imaging of Brain Estrogen Receptors N/A
Completed NCT01172574 - Motor Control Exercise in Osteoporotic Women N/A
Completed NCT00530582 - Progesterone Reduces Wakefulness in Sleep EEG and Has no Effect on Cognition in Healthy Postmenopausal Women Phase 4
Completed NCT01825785 - A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785) Phase 1
Completed NCT04364061 - Post Exercise Substrate Oxidation, Appetite and Energy Intakes in Overweight/Obese Postmenopausal Women (EScAPE) N/A
Completed NCT03180294 - Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer Phase 2
Recruiting NCT06445842 - Short-term Circuit Training on Muscle Mass and Quality of Life in Sedentary Postmenopausal Women N/A
Completed NCT01753908 - Broccoli Sprout Extract in Treating Patients With Breast Cancer Early Phase 1
Not yet recruiting NCT06377631 - Effect of Multi-ingredient on Visceral Adiposity & Non-alcoholic Fatty Liver Disease in Postmenopausal Women With Abdominal Obesity N/A
Recruiting NCT06228768 - Acupressure for Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Patients With Breast Cancer N/A
Terminated NCT01294397 - Effects of Denosumab on the Pharmacokinetics of Etanercept Phase 1